Particle.news
Download on the App Store
8 ARTICLES
·
3h ago

Eli Lilly to Acquire Verve Therapeutics in $1.3 Billion Gene-Editing Deal

This acquisition secures Lilly’s full rights to a Fast Track–designated cardiovascular gene-editing therapy.

Eli Lilly will pay as much as $13.50 per share, the companies said Tuesday.
Image
Image
(Rafael Henrique - stock.adobe.com)

Overview

  • Lilly agreed to buy Verve for $10.50 per share plus up to $3 per share in contingent value rights, valuing the deal at up to $1.3 billion.
  • Shares of Verve jumped about 75% in premarket trading following the announcement.
  • Verve’s lead candidate, VERVE-102, is in a Phase 1b clinical trial and holds FDA Fast Track designation for atherosclerotic cardiovascular disease.
  • The acquisition builds on a 2023 collaboration between the companies and is expected to close in the third quarter of 2025.
  • Verve reported $32.3 million in revenue last year without a profitable quarter, and the deal aligns with Lilly’s expansion of its cardiovascular pipeline.